Our Blog | Biosimilars & Generics | AAM

New Blog - Jonathan Kimball gives more detail re: AAM's blueprint & proposed policy framework

Elderly patient - medicare and low cost generic medicines

May 13, 2020 | Craig Burton

AAM Supports Updating Medicare to Lower Costs for America’s Seniors

Preview of The New York Times article: William Haddad, Crusader for Generic Drugs, Dies at 91

May 13, 2020 | Bob Billings <

Thank You, Bill Haddad

AAM Blueprint for U.S. Pharmaceutical Supply Chain - header

Apr 30, 2020 | Jonathan Kimball

AAM’s Plan for Strengthening the Generic Drug Supply Chain

Protective Mask - COVID-19

Mar 30, 2020 | Jeff Francer

COVID-19: This Week’s Initiatives From the Generic and Biosimilars Industry

COVID-19 Response - Patient Access to Medicines

Mar 19, 2020 | Jeff Francer

AAM’s COVID-19 Response: Helping Patients and Families Meet Their Health Care Needs

Mar 18, 2020 | Joseph Stewart

Top 10 Ways to Commemorate the 10th Anniversary of Biosimilars in the U.S.

Coronavirus

Feb 28, 2020 | Jeff Francer

AAM Interim CEO Jeff Francer on COVID-19

Feb 28, 2020 | Erica Klinger

Stories and Data: How AAM Equips Advocates in the States

Feb 27, 2020 | Erik Komendant

The First (Price) Cut Is the Steepest

Feb 25, 2020 | Sara Skubikowski

Savings by Condition: The Latest Data

Jan 9, 2020 | Karin Hessler

Competition Matters. That’s Why We Need to Further Improve IPR.

Dec 18, 2019 | Kristin Murphy

Women-Powered Health Policy: 500 and Counting